SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) approved ...
Despite being the most common vaginal condition,1 BV symptoms are often mistaken for a yeast infection2 JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a ...
Clindamycin is an antibiotic. It works to treat bacterial infections when penicillin is not an option. A doctor may recommend clindamycin for certain respiratory infections, lung infections, blood ...
LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food ...
LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...
Details concerning the Clindamycin Phosphate combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...
This combination medication contains an antibiotic and drying agent, prescribed for acne.
On Wednesday, September 20, the pharmaceutical company Zydus Lifesciences Ltd. announced that it has attained a critical milestone by receiving final approval from the US Food and Drug Administration ...
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of clindamycin phosphate foam, 1%. Glenmark’s clindamycin phosphate foam, 1% is bioequivalent and therapeutically equivalent to the ...
Clindamycin is an antibiotic doctors prescribe to treat tooth infections, particularly if you’re allergic to penicillin. It’s safe for most people but may cause digestive side effects, and should ...
Please provide your email address to receive an email when new articles are posted on . 52.7% of pediatric patients treated with the triple-combination gel vs. 24% of vehicle-treated patients achieved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback